Mycobacterium tuberculosis (Mtb) DNA gyrase ATPase was the target of a tuberculosis drug discovery program. The low specific activity of the Mtb ATPase prompted the use of Mycobacterium smegmatis (Msm) enzyme as a surrogate for lead generation, since it had 20-fold higher activity. Addition of GyrA or DNA did not significantly increase the activity of the Msm GyrB ATPase, and an assay was developed using GyrB alone. Inhibition of the Msm ATPase correlated well with inhibition of Mtb DNA gyrase supercoiling across three chemical scaffolds, justifying its use. As the IC 50 of compounds approached the enzyme concentration, surrogate assays were used to estimate potencies (e.g., the shift in thermal melt of Mtb GyrB, which correlated well with IC 50 s >10 nM). Analysis using the Morrison equation enabled determination of K i app s in the sub-nanomolar range. Surface plasmon resonance was used to confirm these IC 50 s and measure the K d s of binding, but a fragment of Mtb GyrB had to be used. Across three scaffolds, the dissociation half life, t 1/2 , of the inhibitortarget complex was ≤8 min. This toolkit of assays was developed to track the potency of enzyme inhibition and guide the chemistry for progression of compounds in a lead identification program.
Introduction
History has taught us that emergence of resistance to antimicrobial agents is inevitable, with the consequence that there will generally be a need for new anti-infective agents. In addition, since the current therapies for tuberculosis were discovered several years ago, there is a need for better and more effective treatments to save the over 1.4 million patients who die of this disease every year. 1 The pharmaceutical industry is continuously on the search for new targets and starting points for drug discovery programs. Recently, emphasis has shifted from highthroughput screening (HTS) of genomics-derived targets to the use of clinically validated targets while searching for novel inhibitors or novel mechanisms of inhibition of these. One such target is DNA gyrase, which offers a mechanism that has not been fully exploited, that of its ATPase activity. DNA gyrase is an enzyme with two subunits, GyrA and GyrB, which introduces negative supercoils into DNA in an adenosine triphosphate (ATP)-dependent reaction, thus controlling the topological state of DNA in the bacterial cell. Classic inhibitors of the supercoiling activity are the fluoroquinolones, molecules that bind primarily the GyrA subunit and are widely used to treat antibacterial infections, including drug-resistant tuberculosis. However, resistance to the fluoroquinolones is slowly eroding the power of this class of antibiotics. 2 The ATPase activity of DNA gyrase can be uncoupled from its supercoiling activity and measured in isolation. Inhibition of the ATPase inhibits supercoiling; hence, inhibitors of this activity would be expected to be effective antibacterial agents. Targeting this activity offers an opportunity to develop novel anti-TB or antiinfective agents.
Assays have been developed to screen for inhibitors of GyrB ATPase. Novobiocin targets the GyrB ATPase; in addition, other chemical classes of GyrB ATPase inhibitors [3] [4] [5] [6] [7] and co-crystal structures of many of these binding to GyrB are also reported. Mycobacterial DNA gyrase subunits have been purified from Mycobacterium smegmatis (Msm) or as recombinant proteins expressed in Escherichia coli. 8, 9 Virtual screening of the GyrB subunit 10 as well as a high-throughput screen 5 have been used to identify GyrB ATPase inhibitors. In addition, compounds with cellular activity against Mycobacterium tuberculosis (Mtb) have been developed without measuring the activity against the enzyme. 11 However, no reports have characterized the residence time or energetics of binding of compounds to GyrB. Compounds with a long residence time or t 1/2 are expected to have an advantage in vivo, since compound effects can last beyond the time when compounds are cleared from the body. 12 The energetics of binding is useful in lead optimization, since inhibitors that are more specific to the target and also best in class compounds have an enhanced enthalpic binding component. 13 An accurate estimation of target potency (i.e., K d or IC 50 ) is critical in drug discovery programs to be able to drive the chemistry toward improvement of the affinity of inhibitors for the target. This is coupled with a need to use assays that are tractable and relatively high throughput. Quite often, a compromise has to be made and a surrogate used instead of the ideal assay. Described here is the development of mycobacterial DNA gyrase as a drug target and a toolkit of surrogate enzyme assays or analytical methods, beyond the primary assay, that was necessary to determine the potency of enzyme inhibition and guide the medicinal chemistry for progression of hits for the treatment of tuberculosis.
Materials and Methods

Materials
ColorLock malachite green reagent for the detection of inorganic phosphate (Pi) was from Innova Biosciences (Cambridge, UK). All other chemicals, unless otherwise specified, were from Sigma-Aldrich (St. Louis, MO).
Measurement of Cellular Activity against Mtb or Msm
Inhibition of the growth of Mtb or Msm was measured as described in the supplementary file. The minimum inhibitory concentration (MIC) was used as a measure of cellular activity of the compounds.
Cloning, Expression, and Purification of Mtb and Msm DNA Gyrase
Full-length Mtb gyrA and gyrB were cloned into pET20b and pET19b, respectively, as His-tagged proteins, with
GyrA having a C-terminal His tag and GyrB an N-terminal His tag. Mtb DNA gyrase holoenzyme was purified from recombinant GyrB and GyrA subunit proteins expressed in E. coli as described. 14 A ~26-kDa fragment of Mtb gyrB (Gln20 to Gly266) was cloned into the pET20b vector and expressed in E. coli. Cells were lysed by freeze-thaw cycles or sonication. An ammonium sulfate precipitate (30%-50% saturation) was purified by novobiocin affinity chromatography; novobiocin was coupled to epoxy-activated sepharose in 200 mM sodium carbonate buffer (pH 9.5) overnight, followed by blocking of unreacted groups using ethanolamine. Mtb GyrB bound to the column and was eluted with 6 M urea, dialyzed, and concentrated. The concentrated eluate was further purified by gel filtration on a Superdex 200 (GE Healthcare, Piscataway, NJ, USA) column (320 mL). The protein was stored in 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, and 10% glycerol in aliquots at -70 °C.
Msm gyrB was expressed and purified as described earlier from E. coli BL21 star (DE3) pLysS cells. 14 Briefly, E. coli cell pellets were lysed in a pH 7.5 Tris-HCl buffer containing glycerol, EDTA, dithiothreitol (DTT [TGED]), and protease inhibitors. Nucleic acids were precipitated by addition of streptomycin sulfate followed by ultracentrifugation. A 35% to 55% ammonium sulfate fraction of the supernatant was dissolved in and dialyzed against TGED buffer with 100 mM NaCl; this was loaded onto an anion exchange column (MonoQ, GE Healthcare, Piscataway, NJ, USA). The flow-through of the MonoQ column was loaded onto a heparin sepharose column. GyrB was eluted with a linear 0.1 to 1 M NaCl gradient; active fractions were pooled; concentrated; dialyzed against TGED, 100 mM NaCl, and 1 mM DTT; and stored in aliquots at -70 °C.
Both mycobacterial GyrB preparations contained a novobiocin-resistant ATPase, which was reduced to ≤15% of total ATPase by the use of heparin sepharose during purification.
Msm gyrA was cloned, expressed, and purified from E. coli as described (supplementary information). Msm holoenzyme was reconstituted prior to the start of the reaction by incubating GyrB and GyrA at a ratio of 1:3 and in the presence (or absence) of 12 µg/mL DNA on ice, in a buffer containing 50 mM HEPES (pH 7.5), glycerol 10%, EDTA 1 mM, 100 mM K-glutamate, 2 mM DTT, 0.002% Brij-35, and 0.1 mg/mL bovine serum albumin (BSA).
Preparation of DNA. Salmon testes DNA (100 mg, D-1626; Sigma-Aldrich) were dissolved in 12 mL of autoclaved distilled water by stirring at room temperature for 2 h. NaCl was added to 1 M and the DNA was extracted with phenol followed by chloroform-isoamyl alcohol. The aqueous phase was diluted 10-fold in 10 mM Tris-HCl (pH 8), 1 mM EDTA and then sonicated to get an average sheared DNA size of 1000 base pairs.
DNA Gyrase ATPase Assays and Determination of IC 50 and K i app
Msm GyrB ATPase. Assays were performed at 25 °C in a 50-µL volume in 96-well half-area plates (Costar 3695; Corning, Corning, NY) for 130 min. The reactions contained Msm GyrB (15 nM), 50 mM HEPES (pH 7.7), 250 mM potassium glutamate, 200 mM KCl, 1 mM DTT, 0.001% Brij-35, 2% glycerol, 4% DMSO, and 0.65 mM ATP. The reaction was started by addition of 2.5 mM MgCl 2 . At the end of the reaction, 12.5 µL of P i Colorlock Assay reagent (cat. 303-0125; Innova Biosciences) was added, followed 5 min later by addition of 5 µL of stabilizer. Absorbance was measured at 630 nm after 30 min in a Spectramax-250 from Molecular Devices (Sunnyvale, CA). This complete reaction is called the positive control or "Max." The A 630 in the presence of 1 µM novobiocin (Sigma N-1628) was taken as the "background" or "Min" value, and to avoid interference by any novobiocin-resistant ATPase, this value was subtracted from all reactions as a measure of enzyme activity. Compounds were dissolved in DMSO and serially diluted in DMSO, and 2 µL of this stock was used in a 50-µL enzyme reaction to give final compound concentrations in the desired range.
Pi Detection for an HTS-Compatible Assay. For an HTScompatible format, a published method 15 was modified to enable addition of a single reagent. Reagents A, B, and C were prepared and stored separately (reagent A: 0.12% w/v malachite green in 6 N sulfuric acid; reagent B: 7.5% ammonium molybdate; reagent C: 11% Tween 20). Just before use, the "detection reagent" was prepared by mixing the reagents in a ratio of 10:2.5:0.2 (A:B:C), and this was then diluted 3-fold with water (1 [A-B-C mix]:3 water). An equal volume of detection reagent was added to the reaction in the well of the microplate to stop the enzyme assay, the contents were mixed, and the A 630 was read 30 min later.
ATPase reaction: 
ATP
Thermofluor Assay
Measurements of shifts in the melting temperature (T m ) of Msm GyrB protein were carried out in 50 mM HEPES (pH 7.7), 250 mM potassium glutamate, 200 mM KCl, 1 mM DTT, 0.001% Brij-35, 2% glycerol and 2.5 mM MgCl 2 , 4% DMSO, and 0.1 mg/mL of enzyme ± test compounds (50 µM). In addition, 5× Sypro Orange (S-6650; Invitrogen, Carlsbad, CA) was used as a fluorophore. Assays (20 µL) were set up in 96-well PCR plates (Axygen-PCR-96-FLT-C; Corning LifeSciences, Tewksbury, MA, USA), sealed with Microseal B (Bio-Rad, Hercules, CA). The temperature was varied from 25 °C to 95 °C in steps of 0.5 °C, and fluorescence measurements (ex: 470 nm, em: 570 nm) were carried out in an iCycler from Bio-Rad. Fluorescence was plotted versus the temperature. In addition, the rate of change of fluorescence with temperature (-ΔRFU/dT) was plotted versus temperature, and the minimum point of the derivative curve was taken as the melting point (T m ).
Mtb DNA Gyrase Supercoiling Assay. The assay was performed in 30 µL for 130 min at 37 °C as described. 14 Supercoiled and relaxed forms of DNA were separated by gel electrophoresis on 0.8% agarose in a buffer containing 45 mM Tris-borate and 1 mM EDTA for 16 h at 1 V/cm. Gels were stained with ethidium bromide (0.7 µg/mL), and the density of relaxed and supercoiled forms was analyzed using the Bio-Rad gel documentation system to compare % conversion of relaxed to supercoiled forms. A unit was defined as the conversion of 100 ng of relaxed plasmid to the supercoiled state in 1 h at 37 °C.
Surface Plasmon Resonance (BIAcore) Studies
Experiments were performed with a BIAcore 3000 system (BIAcore AB, GE Healthcare, Piscataway, NJ, USA) at 25 °C. The N-terminal (26-kDa) fragment of Mtb GyrB was immobilized on a CM5 chip in flow cell 2 (FC2) by covalent amine coupling as recommended by the manufacturer (Biacore Sensor Surface Handbook BR-1005-71 Edition AB). Flow cell 1 (FC1), which was activated and blocked without injecting the protein, was used as a reference cell. Compounds were dissolved in running buffer HBS-P (cat. BR100368; GE Healthcare, Piscataway, NJ) and injected at a flow rate of 60 µL/min. After an association phase of 4 min, the system was switched back to running buffer, and the dissociation phase was followed for at least 10 min; for compounds with longer residence time (>5 min), the dissociation phase was monitored for a longer period (~60 min).
BIAevaluation software was used to analyze the data using the 1:1 interaction model with mass transfer correction. The association rate constant (k on ), dissociation rate constant (k off ), and the equilibrium dissociation constant (K d ) calculated using the kinetic parameters (K d = k off /k on ) are reported. The residence time of the ligand on the protein (1/k off ) or the dissociation half-life (t 1/2 ), 0.693/k off , of the enzyme-inhibitor [EI] complex was calculated.
Isothermal Titration Calorimetry
The energetics of binding of novobiocin to full-length Mtb GyrB protein and the 26-kDa fragment was studied using VP-ITC (MicroCal LLC, Northampton, MA, USA). The protein was dialyzed against 50 mM Tris-HCl (pH 7.5), 6% glycerol, 2 mM DTT, 50 mM KCl, and 5 mM MgCl 2 . The proteins and novobiocin were diluted to a final concentration of 3 µM and ~20 µM, respectively, in degassed dialysis buffer. DMSO and Brij-35 were added to both protein and novobiocin stock to achieve a final concentration of 2% and 0.001%, respectively. The solution of enzyme was titrated with successive additions of 10-µL aliquots of novobiocin (every 3.5 min) at 30 °C. The binding data were corrected for heat of dilution of the compound. The corrected data were analyzed by nonlinear regression using a single-site binding model in Origin software (MicroCal), which yielded the values of equilibrium dissociation constant (K d ) and change in enthalpy (ΔH).
Results
Development of DNA Gyrase Enzyme Assays; Msm as a Surrogate for Mtb
Mtb DNA Gyrase. An assay to measure the ATPase activity of Mtb DNA gyrase was explored. No ATPase activity was detected with Mtb GyrB alone (500 nM) or if only GyrA or DNA was added to it. For Mtb GyrB ATPase activity, addition of both GyrA and DNA was required (Fig. 1) . The ATPase activity of the Mtb holoenzyme plus DNA was enhanced by the addition of glutamate in the assay buffer; however, despite all attempts to enhance the ATPase activity, by varying assay components or increasing the length of the assay, a concentration of 150 to 300 nM GyrB was needed to give a window that was reproducible and robust (Z′ > 0.5). 16 Having this concentration of enzyme would theoretically limit the minimum measurable IC 50 value to 75 nM, since IC 50 = K i app + ½ [E] T , 17 where K i app is the apparent dissociation constant for enzyme inhibitor complex, before correction for the inhibitor modality-specific influence of substrate concentration relative to K M ; IC 50 and K i app can be treated interchangeably in steady-state kinetics, where [E] T is much lower than the K i app . However, for "potent" compounds (tight binding inhibitors)-that is, when K i app approaches the enzyme concentration-this steady-state assumption does not hold, and the IC 50 values underestimate the true affinity of the inhibitor for the enzyme. 18 The inability to use IC 50 s to estimate the affinity of inhibitors with K i app <75 nM, using Mtb DNA gyrase, posed a serious limitation to driving an IC 50 -based structure-activity relationship (SAR), because it was expected that K i app s in the single-digit nanomolar range would be needed to achieve sub-micromolar cellular activity; this reason alone has often led to the elimination of targets from our discovery programs. This prompted consideration of M. smegmatis (Msm) DNA gyrase as a surrogate for our drug discovery program. To ensure that the activity on the Msm enzyme was similar to that on the Mtb enzyme, and since the aim was to develop compounds with cellular activity against Mtb, a gel-based assay to measure supercoiling activity of Mtb DNA gyrase Msm DNA Gyrase. The ATPase activity of Msm GyrB, unlike that of Mtb GyrB, was only slightly enhanced by the addition of GyrA subunit or DNA and varied from 30% to 100% enhancement of activity across protein batches (Fig.  1) . The major ATPase activity was associated with Msm GyrB alone, in contrast to an earlier report 19 in which the protein was exposed to low pH during purification and no ATPase was detectable in a radioactive assay with 450 nM GyrB. The specific activity of GyrB alone was 350 to 900 nmol ATP hydrolyzed/min/mg GyrB protein, and an assay was optimized using 15 nM GyrB. This is 10 to 20 times lower than the concentration of Mtb GyrB needed for a similar window, giving the advantage of being able to theoretically measure IC 50 s of inhibitors in the ~15 nM range, rather than the ~300 nM range for the Mtb enzyme.
The conditions for a microplate assay for Msm GyrB ATPase were optimized by testing the effect of buffer composition (e.g., salts and pH) on the assay. Both KCl and K-glutamate stimulated the activity of GyrB ATPase, but a combination of the two showed better activity than either KCl or K-glutamate alone. For example, addition of glutamate caused a ~50% to 100% increase in activity even in the presence of 300 mM KCl. The combination of 250 mM K-glutamate and 200 mM KCl was found to give highest activity and was chosen for further assays (Fig. 2A) .
The effect of Brij-35, BSA, and glycerol on the ATPase activity was tested using a "factorial design of experiment" 20 (Suppl. Fig. S1 ). Brij-35 was added at 0%, 0.001%, or 0.002% and BSA at 0, 0.02, 0.05, or 0.2 mg/mL. Glycerol did not have a significant effect on the activity up to 10%. Addition of either BSA (0.02 or 0.05 mg/mL) or Brij-35 caused a 2-to 2.5-fold increase in GyrB activity. BSA had no effect on the activity in the presence of 0.001% or 0.002% Brij-35. Hence, either BSA or Brij-35 could have been used; Brij-35 was preferred over BSA since it helps eliminate inhibition due to nonspecific compound binding 21 and avoids BSA-dependent modulation of IC 50 s of compounds that are highly protein bound.
A steep drop in activity was observed when the pH reduced below pH 7.4 (Fig. 2B) . Activity between pH 7 and 8, in smaller increments, was tested in HEPES buffer, and a pH of 7.7 was chosen for further experiments (Fig. 2C) . Interestingly, the Msm ATPase activity at 37 °C was lower than at 25 ° or 30 °C and could be due to instability of the protein at this temperature. For convenience, 25 °C was chosen for routine screening (Fig. 2D) . The K M of ATP for Msm GyrB, averaged over four experiments, was 0.65 mM ( Fig. 2E) . This resulted in the final assay screening conditions described in the Materials and Methods section, with ATP concentration close to the K M .
Adaptation to HTS. ATP hydrolysis during assay optimization was measured by detection of inorganic phosphate (Pi) using a commercial kit that gave a signal that was very stable with time, but it needed addition of two separate reagents. Other protocols for malachite green based detection of Pi were explored to make the assay HTS compatible, 3, 15, 22 and one of these 15 was modified to enable a single addition of the detection reagent, which was dispensed using a multidrop. Unlike P i Colorlock, this reagent caused a gradual increase in A 630 over time, but since the rate of increase of the background (Min) and the complete (Max) enzyme reactions was similar, the ΔA 630 remained constant over time, and readings could be taken up to 30 min after termination of the enzyme reaction.
The Z′ 16 of the Msm ATPase assay was 0.8, and an HTS of a million compounds from the AstraZeneca library resulted in the identification of the aminopyrazinamide series. 5 The initial hit had an IC 50 of 2 µM and cellular activity on Mtb (MIC) of 16 µg/mL. Artifacts due to assay readout and false positives were eliminated by a parallel dose-response plate without enzyme, followed by confirmation of inhibition in the Mtb DNA gyrase gel-based plasmid supercoiling assay. 5 The same microplate assay was also used to progress two other ATPase inhibitor chemical series (pyrrolamides 14 and thiazolopyridine ureas 7 ) in a drug discovery program to improve the MIC, pharmacokinetics, and other properties (Fig. 3A) . The thiazolopyridine ureas were identified from a pharmacophore-based search of the AstraZeneca library, 7 whereas the pyrrolamides 14 were a follow-on of a broadspectrum antibacterial program within the company. Initial compounds in the thiazolopyridine ureas had an IC 50 of ~0.16 µM and an MIC of ~8 µg/mL, 7 whereas the pyrrolamides had similar IC 50 s but lower MICs (~1 µg/mL). 14 Lead identification efforts resulting in compounds efficacious in mouse models of tuberculosis have been described recently. 7, 14 Here is described the biochemical and biophysical assays that were necessary and that enabled progression of the three series to compounds with greatly increased potency of enzyme inhibition (≤2 nM IC 50 s) and Mtb MICs as low as 0.03 µg/ml (Suppl . Table S3 ).
Validation of Msm GyrB as a Surrogate for the Mtb Enzyme.
A selection of compounds covering all three series was tested on Msm GyrB ATPase and for inhibition of Mtb DNA gyrase supercoiling activity, with ATP concentration at the respective K M s for the two enzymes. The IC 50 in the two assays were similar (Fig. 3B) , confirming that Msm is a good surrogate for Mtb and that the Msm ATPase assay was able to select ATPase inhibitors that inhibit the supercoiling activity of Mtb DNA gyrase. The Msm ATPase assay was used for compound progression with occasional testing on the Mtb supercoiling assay.
Determining the Relative Potency of Compounds Using Thermal Denaturation
An assay with 15 nM GyrB enzyme was adequate for the primary screen. However, as the SAR was established and potent compounds were synthesized (IC 50 s approaching 15 nM; Suppl. Tables S1 and S3), this assay was inadequate to distinguish between compounds, and surrogate assays were explored to be able to rank-order compounds and determine if the compounds being synthesized had improved potency with respect to affinity for the enzyme.
T m Shift. Msm GyrB enzyme had an average melting temperature (T m ) of 49.6 °C with a standard deviation of 0.25 °C across five experiments. On addition of the ATPase inhibitors, two distinct T m s were observed: one marginally lower than the T m of the enzyme and the other higher than the T m of the enzyme; a similar pattern was seen on addition of novobiocin ( Fig. 4A,B) .
A shift of 11 °C was observed for novobiocin, which had an IC 50 of 10 nM. The T m shift was measured for a selection of compounds from the pyrrolamide series. The shift in T m correlated well with the IC 50 of the compounds on Msm GyrB ATPase (Fig. 4C and Suppl. Table S1 ) for compounds with IC 50 >10 nM. However, for potent compounds (IC 50 <10 nM; pIC 50 >8), a wide range of T m shift (7 °C to 13 °C) was observed for compounds with similar IC 50 . It was hypothesized that the T m was measuring the correct potency of the compounds and that the reason for the wide range of T m shift for compounds with IC 50 <10 nM was that as the IC 50 approached the enzyme concentration (15 nM), the IC 50 overestimated the K i app .
The Morrison Equation to Measure K i app s of Potent Compounds
While the T m appeared to rank-order compounds, an accurate estimation of binding affinity of the potent compounds was needed to guide the medicinal chemistry. Options that were explored to enable this included (a) lowering the enzyme concentration [E] while simultaneously increasing the reaction time to lower the influence of [E] T in the IC 50 determination, but a significant reduction in the enzyme concentration resulted in a loss of signal. (b) The ATP concentration in the assay was increased; this should have the effect of raising the IC 50 of a competitive inhibitor and thus enable differentiation of the affinity of compounds in a lower range of K i app . However, the high ATP concentrations significantly increased the background reading and interfered with the assay. (c) Using Morrison's method of analysis 23 to determine the K i app instead of the standard IC 50 determination using the four-parameter equation was found useful and is described below. (d) Use of surface plasmon resonance (SPR), which has the potential to detect K d s in the single-digit pM range, is also described. 24 For IC 50 measurements in general, it is assumed that the concentration of the EI complex, [EI], is very small compared with [I], and hence the free inhibitor concentration is well modeled by the total inhibitor concentration [I]. In the case of tight binders, [EI] = [I], and IC 50 values underestimate the true affinity of the inhibitor for the enzyme. 18 The Morrison equation accounts for tight binding, so it does not assume that the free concentration of inhibitor equals the total concentration and can be used in such cases. A set of compounds with varying potencies from compound series 1 (thiazolopyridine ureas) and 2 (pyrrolamides) was tested for ATPase inhibition, and the same % inhibition data were analyzed by both the standard IC 50 method and by the Morrison equation to determine K i app values. By this method, the K i app s <10 nM (p K i app >8) were estimated for compounds with IC 50 ~10 nM. The shift in T m correlated well with the p K i app (Fig. 4D and Suppl. Table S1); this was unlike the correlation with pIC 50 , where the pIC 50 saturated at ~8 (IC 50 ~10 nM) ( Fig. 4C) and was more or less constant for compounds with T m > 7 °C; this suggests the T m does measure the true potency of the inhibitors and can be used for rank-ordering compounds by the potency of enzyme inhibition.
To investigate the discrepancy between IC 50 and K i app , we tested a set of compounds in the Msm ATPase assay using three enzyme concentrations; K i app and IC 50 values were estimated and plotted (Fig. 4E) . For a compound with K i app of 600 nM, the IC 50 s estimated using 7.5, 15, and 75 nM enzyme were similar (~600 nM). However, for a compound with K i app of 1.3 nM, the IC 50 values estimated using assays with 7.5, 15, and 75 nM GyrB were 4, 5, and 20 nM, respectively; that is, the IC 50 s estimated were much higher than the K i app because [E] contributed significantly to the IC 50 value. Theoretically, the lower limit of IC 50 measurement is expected to be ½[E] or 37 nM for [E] of 75 nM; the value of 20 nM probably reflects the quantity of active enzyme in the assay or is a result of errors associated with protein estimation and IC 50 measurements.
SPR to Measure K d s and Residence Time of Potent Inhibitors
To check if the compounds were more potent than apparent from K i app measurements and for an independent confirmation of potency, we tested the K d s of the most potent compounds by SPR, which can detect K d s in the pM range. 24 SPR also allows determination of residence time of compounds on the protein.
Mtb full-length GyrB was covalently bound to the chip using a variety of conditions, and the effectiveness of the immobilization was tested by studying the binding of novobiocin to the protein. During this optimization, it was discovered that the binding response (RU) did not saturate with increasing novobiocin concentration, even up to 100 µM novobiocin (Fig. 5A) . Considering that the IC 50 of novobiocin on the Msm GyrB ATPase is ~20 nM, it suggested that this was due to nonspecific binding. Increasing the salt or adding detergent to the running buffer did not eliminate the nonspecific binding, and no saturation of the signal was observed with either protein. Subsequently, a 45-kDa fragment of Mtb GyrB was tested with essentially the same result. However, a smaller, 26-kDa Mtb GyrB fragment did not have this problem, and novobiocin showed specific binding to this protein, with typical kinetics and a signal that saturated at ~50 nM novobiocin (Fig. 5B) . The energetics of binding were similar to those obtained by isothermal titration calorimetry measurements of the novobiocin interaction with full-length Mtb GyrB (Suppl . Table S2 ), leading us to conclude that this 26-kDa Mtb GyrB fragment could be used as a surrogate for the full-length protein to study the binding K d s and residence time of ATPase inhibitors.
K d values and the residence time were estimated for compounds across all three classes in the drug discovery program, plus three published inhibitors of DNA gyrase ATPase (compounds 12-14; Suppl. Table S3 ). The shortest dissociation t 1/2 of the [EI] complex for compounds across the three series was 0.1 min (data not shown); the longest t 1/2 measured was 8.3 min (residence time of ~12 min) for compounds 1 and 2, both pyrrolamides. In contrast, a GyrB ATPase inhibitor (compound 14) from a distinct pyridine urea series 25 had a t 1/2 of 56 min (Fig. 5C) , leading to the conclusion that the estimated t 1/2 values of the compounds were not an artifact. The K d values of compounds determined by SPR binding to Mtb GyrB studies were very similar to the K i app values determined by measurement of inhibition of enzyme activity and Morrison equation analysis with the Msm enzyme, providing independent confirmation of the K i app values.
Discussion
The ATPase active site of DNA gyrase is highly conserved between Msm and Mtb. 5 Hence, it is not surprising that compound affinities for the target measured across the two species and across technologies are very similar (e.g., Msm ATPase vs. binding by SPR to an Mtb GyrB fragment). The use of the Msm protein did not hinder development of a robust SAR or lower the MIC against Mtb. However, despite the similarity of the ATPase site, the specific activity of the Mtb DNA gyrase was much lower than that of Msm. The requirement for both subunits of the Mtb homolog to measure the ATPase versus only GyrB for Msm was another difference, and this was an advantage for Msm protein supply. Despite the similarity between Msm and Mtb at the enzyme level, many compounds that inhibited the growth of Mtb had much higher MICs against Msm (200fold for compound 6; Suppl. Table S3 ) or were ineffective, reflecting the difference in the cell wall of the two bacteria. Since compounds were optimized for penetration of the Mtb cell wall, the lack of activity against Msm was not surprising. The ATPase enzyme assay was the backbone of the program driving the chemistry toward increased affinity for the target and was high throughput. The Morrison analysis was very convenient for estimating inhibitor-target affinity when IC 50 values approached the enzyme concentration and was high throughput. Since K i app s of 1.5 nM were estimated using 75 nM total enzyme, it appears that the Morrison analysis can measure K i app values in the range of 1/50th the enzyme concentration. This is a 25-fold improvement over the IC 50 method of estimation of K i app , which is limited to values of ~½[E]. It may be that the Morrison analysis, in practice, has an even lower limit of detection of K i app relative to [E].
The SPR is an attractive technology: it uses a very low quantity of protein and gives rich information (i.e., on and off rates as well as K d s). The dissociation half-life of the [EI] complex for compounds of all three series was ≤8 min. Since the doubling time of Mtb is ~24 h, a t 1/2 of 8 min is unlikely to have any impact in vivo. Immobilization of the protein did not affect the affinity of GyrB ATPase inhibitors, and K d s of inhibitors for the target were very similar to affinities obtained by methods where the protein was not immobilized (e.g., isothermal titration calorimetry [ITC], IC 50 ). While not high throughput, the chip with immobilized Mtb GyrB could be reused and the BIAcore machine programmed to measure K d s of ~15 compounds in a 24-h cycle.
The thermal shift analysis is high throughput, while using a fairly large quantity of protein, and has the advantage of being able to determine affinities of slow binders when coupled with differential scanning calorimetry. 26 However, the magnitude of the shift in T m alone is not directly related to the binding affinity. 27 In the case of this drug discovery program, the T m shift could be used to rank compounds only because, across and within the series, the binding enthalpies were very similar. The binding of all three scaffolds to Mtb GyrB was driven by enthalpy (preliminary ITC data), with ΔΗ and TΔS values in a very similar range to that of novobiocin, suggesting the interactions these compounds make are somehow favored by the nature of the protein binding pocket. The K d of binding of novobiocin to Mtb GyrB is similar to values reported for E. coli and Streptococcus pneumonia. 28, 29 ITC was useful in determining the energetics of binding, but it needs a high amount of protein, is low throughput, and is not able to determine very potent K d s. Both the thermal shift analysis and ITC, while suitable for compound progression in a lead identification program, are not suitable for HTS.
It was unexpected that binding of both the compounds and novobiocin to Msm GyrB would result in two thermal transitions. Interestingly, the published aminopiperidine inhibitors 30 upon binding to the enzyme also appear to cause two thermal transitions. The reason for two T m s could be that there are two populations of the protein, only one of which binds the compound. Or, alternatively, the enzyme has two domains, only one of which binds the compound, hence melting at a higher temperature, while the other domain remains unaffected. Which one of these hypotheses is true is yet to be investigated.
Most published assays for the DNA gyrase ATPase are those used for hit identification. In summary, described here is a toolkit of assays that were necessary beyond the primary assay to drive a lead generation, drug discovery program targeting Mtb DNA gyrase ATPase. The use of surrogates and alternative technologies enabled the progression of diverse scaffolds to increased potency of enzyme inhibition. Starting with an IC 50 of 2 µM, the most potent aminopyrazinamide synthesized had an IC 50 of ~2 nM and an MIC of 0.5 µM and were highly bactericidal, killing Mtb in vitro and in macrophages. 5 The most potent thiazolopyridine ureas synthesized had IC 50 s ~2 nM (Suppl . Table S3 ) and MICs of 0.06 to 0.5 µg/mL; compounds 7 and 9 were efficacious in a murine model of tuberculosis (manuscript in preparation). 7 The best pyrrolamides synthesized had IC 50 s ~2 nM (Suppl . Table  S3 ) and MICs of 0.03 µg/mL; compound 4 was efficacious in a mouse model of tuberculosis. 14 
